Cardiex Limited (ASX:CDX) leverages its proprietary SphygmoCor® technology to develop and market vascular biomarker technologies and digital solutions focused on the world’s largest health disorders. SphygmoCor®, the company’s groundbreaking technology, has set the benchmark for noninvasive measurement of central aortic pressures and related arterial health characteristics, collectively referred to as…
Overview Solar and wind energy are expected to power 90 percent of the world’s electricity by 2050, accelerating the…
Overview As the world approaches what analysts refer to as the point of no return for climate change, governments…
The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within…
Overview Cardiex Limited (ASX:CDX) is an ASX-listed medical technology company leveraging its proprietary SphygmoCor® technology to develop and market…
Overview Impact Minerals (ASX:IPT) is an exploration and development mining company focused on discovering and developing new resource projects…
Victory Battery Metals CORP. (CSE:VR)(OTC PINK:VRCFF)(FWB:VR6) is pleased to announce that it has entered into an option agreement dated…
(TheNewswire) Payment date for the distribution will be April 26, 2024 Coquitlam, BC TheNewswire – April 18, 2024 –…